GRI VS LLY Stock Comparison
Performance
GRI10/100
10/100
GRI returned -91.59% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 10 of 100.
LLY100/100
100/100
LLY returned 68.15% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
Profit
GRI20/100
20/100
Out of the last 4 quarters, GRI has had 1 profitable quarters and has increased their profits year over year on 0 of them.
LLY66/100
66/100
Out of the last 20 quarters, LLY has had 19 profitable quarters and has increased their profits year over year on 6 of them.
Volatility
GRI36/100
36/100
GRI has had a lower than average amount of volatility over the last 12 months giving it a score of 36 of 100.
LLY53/100
53/100
LLY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.
Analyst Price Targets
GRI
"Analyst Price Targets" not found for GRI
LLY68/100
68/100
22 analysts offer 12-month price targets for LLY. Together, they have an average target of 391, the most optimistic target put LLY at 673 within 12-months and the most pessimistic has LLY at 236.
Technicals
GRI
"Technicals" not found for GRI
LLY57/100
57/100
LLY receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.
Earnings
GRI
"Earnings" not found for GRI
LLY10/100
10/100
LLY has missed earnings 7 times in the last 20 quarters.
Dividend
GRI
"Dividend" not found for GRI
LLY100/100
100/100
LLY's most recent dividend was $0.57 per share, based on a share price of $588.54. It was a payout ratio of 50.90% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
GRI Bio, Inc. Common Stock Summary
Nasdaq / GRI
Healthcare
Biotechnology
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Eli Lilly & Co. Summary
New York Stock Exchange / LLY
Healthcare
Drug Manufacturers - General
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare GRI to other companies in the same or a similar industry.